This article is
- freely available
Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
Karolinska Institutet, Department of Clinical Science and Education, Division of Internal Medicine, Unit for Diabetes Research, Södersjukhuset, SE-118 83 Stockholm, Sweden
Received: 15 January 2010; in revised form: 3 March 2010 / Accepted: 19 March 2010 / Published: 22 March 2010
Abstract: Although advances have been achieved in the management of type 2 diabetes, current treatment options for patients with this disease still fail to address disease progression, glycaemic control remains suboptimal and therapies are often associated with weight gain and hypoglycaemia. Thus, new antidiabetes therapies are being sought. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that have been the recent focus of research. The physiological action of GLP-1, in particular, has demonstrated its potential in addressing the therapeutic needs of patients with type 2 diabetes. To exploit this action, liraglutide, a human GLP-1 analogue that shares 97% of its amino acid sequence identity with native GLP-1, has been developed. In a recent phase 3 trial programme (LEAD, Liraglutide Effect and Action in Diabetes), treatment with liraglutide was associated with substantial improvements in glycaemic control and low risk of hypoglycaemia. In addition, reductions in weight and systolic blood pressure were reported. There is also an indication that liraglutide is capable of improving β-cell function and increasing β-cell mass. Thus, liraglutide may overcome the limitations with current therapies and help to address the unmet clinical needs of patients with type 2 diabetes.
Keywords: GLP-1; liraglutide; LEAD; glycaemic control; type 2 diabetes
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Sjöholm, Å. Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs. Pharmaceuticals 2010, 3, 764-781.
Sjöholm Å. Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs. Pharmaceuticals. 2010; 3(3):764-781.
Sjöholm, Åke. 2010. "Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs." Pharmaceuticals 3, no. 3: 764-781.